Study of ADR-002K for Heart Failure Patients Having Bypass Surgery
Treatments studied
Part of Heart & circulation clinical trials.
This study tests an experimental drug (ADR-002K) for people with heart failure caused by blocked arteries who are about to have bypass surgery. The goal is to see if it helps the heart recover better after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic heart failure caused by blocked arteries in your heart.
- You are scheduled to have coronary artery bypass surgery (CABG).
- Your ejection fraction (pumping strength) is less than 40%.
- You do not have severe heart valve disease.
- You have not had a heart attack or unstable angina in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cells from donated umbilical cord blood can improve heart function in people with heart failure caused by blocked arteries. You'll receive one or more infusions of these cells through a vein.
This study tests a new treatment using donor stem cells injected into the heart during scheduled bypass surgery. The goal is to see if these cells help improve heart function in people with heart failure due to blocked arteries and a weak heart pump.
This study looks at a treatment that affects signals between heart cells in people with severe coronary artery disease who are scheduled for bypass surgery. The goal is to see if changing these heart-cell signals can improve heart outcomes around the time of surgery.
This trial tests whether injecting stem cells from umbilical cord tissue into the heart muscle during bypass surgery can improve heart function in people with chronic heart failure. It is for patients who are already scheduled for bypass surgery and have a weakened heart pump (LVEF between 21% and 40%).
This study looks at tiny structures inside heart muscle cells (especially “power stations” in the cells) in people with certain types of heart failure who are getting coronary bypass surgery. It may help researchers better understand what changes happen in the heart and how this could guide future care.
This trial tests a drug called EA-230 that may help people recover faster after heart bypass surgery. If you are having planned bypass surgery, this drug might shorten your hospital stay.
Hear when a new Ischemic Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.